中国生物制药：礼新医药与默沙东就LM-299达成全球独家授权协议

Group 1 - The core point of the article is that China National Pharmaceutical Group's subsidiary, Lixin Pharmaceutical, has reached a global exclusive licensing agreement with Merck for LM-299, which includes significant financial terms [2] - Under the agreement, Merck will receive exclusive rights for the global development, production, and commercialization of LM-299 [2] - Lixin Pharmaceutical will receive an upfront payment of $588 million, along with potential milestone payments that could total up to $2.7 billion [2]